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The naturally-occurring cyclic cystine-knot microprotein trypsin inhibitors MCoTI-I and MCoTI-II 
have been synthesised using both thia-zip native chemical ligation and a biomimetic strategy 
featuring chemoenzymatic cyclisation by an immobilised protease. Engineered analogues have 
been produced containing a range of substitutions at the P1 position that redirect specificity 10 
towards alternative protease targets whilst retaining excellent to moderate affinity. Furthermore, 
we report an MCoTI analogue that is a selective low-µM inhibitor of foot-and-mouth-disease virus 
(FMDV) 3C protease, the first reported inhibitor of this important viral enzyme. 
Introduction 
Cyclotides1,2 are a unique class of head-to-tail cyclic cysteine-15 
rich microproteins up to 37 amino acids in length that exhibit 
a wide range of biological properties, ranging from anti-HIV3-
5 to insecticidal activity.6,7 In contrast to many smaller 
naturally occurring cyclic peptides they are true gene 
products, and possess a highly stable cystine-knot† topology, 20 
whereby two disulfide bridges form a ring through which a 
third is threaded.8-10 This combination of intricate structure, 
diverse biological activity and unusual biogenesis has inspired 
a growing research effort directed towards understanding the 
synthesis and function of cyclotides both in the cell and in 25 
vitro.7,11-13 In addition, their high resistance to degradation in 
vivo has attracted recent and widespread interest in the 
potential of cyclotides as scaffolds to present structured 
protein domains for therapeutic applications.14-17 To date, 
cyclotides have been isolated from a variety of plant species, 30 
including Cucurbitaceae (genus Momordica),18,19 Rubiaceae20 
and Violaceae,21,22 where they are thought to act as 
antifeedants.7 Recent work, most notably by the Craik group, 
has provided the three-dimensional structures of a wide range 
of cyclotides by NMR.23 Syntheses of several small to 35 
medium size cyclotides have been reported24-28 
 The cyclotides MCoTI-I and MCoTI-II were first isolated 
from the dormant seeds of Momordica cochinchinensis, and 
have been shown to be very potent (sub-nM) inhibitors of 
trypsin.18 Whilst the MCoTI trypsin inhibitor cyclotides do 40 
not share significant sequence homology with other cyclotides 
beyond the presence of the three cystine bridges, solution 
NMR has shown that they do indeed adopt a backbone-cyclic 
cystine-knot topology (Fig. 1). The binding mode of these 
cyclotides is likely to be similar to that of related cystine-knot 45 
trypsin inhibitors such as EETI;17,29,30 however, their 
rigidifying cyclic backbone contributes both enhanced 
stability and increased potency in comparison to these simpler 
structures.  
 As part of our ongoing studies on the potential of cyclotides 50 
as stable scaffolds for drugs or as tools for chemical genetics31 
we wished to explore whether the structure of the MCoTI 
cyclotides may be re-engineered to exhibit novel inhibitory 
activity. Furthermore, previous studies suggest that cyclotides 
from Rubiaceae and Violaceae form via protease-mediated 55 
ring closure at a conserved motif,7,12,32,33 and we hypothesised 
that the total synthesis of MCoTI cyclotides might be 
achieved via a biomimetic protease/ligase pathway. Here we 
report in full our recent studies in these two areas,34,35 and 
describe the activity and selectivity of natural and engineered 60 
MCoTI cyclotides for a range of proteases. We also discuss 
the potential implications for future work aimed at realising 
the full potential of cyclotides as tools in medicinal and 
chemical biology. 
MCoTI-II: X1 = X2 = K
MCoTI-I: X1 = Q, X2 = R
SGSDGGVCPKILX1X2CRRDSDCPGACICRGNGYCG
 65 
Figure 1 Solution NMR structure of MCoTI-II and sequences of the 
known naturally-occurring MCoTI cyclotides, MCoTI-I and -II.18,36 Key 
residues in the active loop (Pro9, Lys10, Ile11) and the cystine bridges are 
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highlighted. Red: alpha helix; green: backbone; yellow: disulfide bridges. 
Structure rendered with PyMOL.37 
Results and Discussion 
Chemical synthesis of engineered MCoTI cyclotides 
Total synthesis of an engineered cyclotide presents three key 5 
challenges: 
 
1. Synthesis of the backbone, which in the case of MCoTI 
contains a sensitive Asp-Gly sequence. 
2. Head-to-tail backbone cyclisation. 10 
3. Oxidative protein folding to form the three disulfide bonds 
in the correct cystine-knot geometry. 
 
In practise, the strategy adopted for backbone synthesis lays 
the foundation for correct cyclisation and folding, and this 15 
may be approached using a range of methodologies. Boc-,38 
microwave-enhanced24 and Fmoc-14,30,34,35 based solid-phase 
peptide synthesis (SPPS) have all been used for cyclotide 
backbone construction, whilst recent work has shown that 
bacterial expression can also be an effective approach for 20 
smaller scale production of the cyclotide backbone.25,28  
 Backbone cyclisation may then be achieved by exposing a 
suitably side chain protected backbone peptide bearing an 
amino N-terminus and a carboxy C-terminus to standard 
peptide coupling conditions, but this approach suffers from 25 
multiple drawbacks including poor peptide solubility and the 
need for high dilution. Thia-zip native chemical ligation (TZ-
NCL), a technique first pioneered by the Tam group,39,40 has 
emerged as the most effective method for backbone 
cyclisation of cysteine-rich cyclic peptides, and is particularly 30 
applicable to the synthesis of cyclotides.  
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Scheme 1 Schematic representation of thia-zip native chemical ligation 
(TZ-NCL). Ring expansion occurs via an inter-converting series of 
macrothiolactones, the largest of which can be trapped by an N-to-C 35 
rearrangement (NCL) to yield the target macrolactam. 
 In this approach, an unprotected backbone peptide bearing 
an N-terminal cysteine and a C-terminal thioester is simply 
dissolved in a suitable buffer triggering a spontaneous cascade 
cyclisation reaction, resulting in eventual formation of a 40 
macrocyclic thioester that undergoes native chemical ligation 
to the target head-to-tail cyclic peptide (Scheme 1).The 
presence of multiple internal cysteine residues greatly 
accelerates the cyclisation by providing a series of thiolactone 
intermediates of inferior ring size that are readily populated 45 
under equilibrium conditions, and are eventually converted 
into the target compound by irreversible macrolactamisation 
of the largest ring via NCL. Similarly, in the bacterial 
expression of cyclotides constructs bearing a C-terminal intein 
permit a similar mechanism to operate.28 Despite the 50 
potentially problematic synthesis of a C-terminal thioester, the 
overall sequence of SPPS followed by TZ-NCL has proven to 
be significantly more efficient and reliable than the analogous 
peptide bond formation at high dilution, and may be 
performed at relatively high concentration without detectable 55 
formation of oligomeric by-products. 
 Subsequent formation of the three disulfide bonds in the 
correct configuration is highly dependent on the inherent 
propensity of the cyclotide to adopt a cystine-knot.8 In some 
cases, differential protection of cysteine residues with 60 
acetamidomethyl aminoacetal (Acm) groups is required to 
direct sequential formation of one or two disulfide bonds, 
followed by forced oxidation to the native state.39 
Unfortunately, this approach may reduce the efficiency of TZ-
NCL due to reduced availability of internal cysteine residues, 65 
and disulfide bond exchange tends to reduce the purity of the 
final product. However, a recent systematic study on the 
mechanism of oxidative folding of plant-derived MCoTI-II by 
Craik et al. demonstrated that it has a strong tendency to 
adopt the native cystine-knot conformation,9 so we did not 70 
anticipate significant problems with this step. 
 We therefore chose to adopt Fmoc-based SPPS synthesis of 
the backbone thioester followed by TZ-NCL for the total 
synthesis of MCoTI cyclotides and analogues. The Ala22-
Cys23 amide bond was selected as the optimal position for 75 
backbone cyclisation, since among the possible Xaa-Cys 
disconnections it presents the lowest hindrance to NCL. SPPS 
was carried out on a sulfamylbutyryl ‘safety-catch’ linker41 
after loading of the C-terminal alanine residue under 
optimised conditions, as shown in Scheme 2. Activation and 80 
displacement of the resultant C-terminal sulphonamide was 
best achieved with iodoacetonitrile and ethyl 
3-mercaptopropionate, resulting in excellent overall yield of 
linear thioester with respect to a sequence of 60+ synthetic 
steps. Introduction of the sensitive Asp-Gly motif as a 85 
dipeptide bearing a hydroxy-4-methoxybenzyl (Hmb)42 
protecting group on the glycine backbone nitrogen to suppress 
aspartimide formation was found to be essential, and omission 
of this group resulted in only trace quantities of linear product 
from SPPS.  90 
 This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  3 
H2N S
O
O
H
N S
O
O
AFmoc
H
N S
O
O
CICRGNGYCGSGSDGGVCPX3ILX1X2CRRDSDCPGABoc
S COOEt
Tr t
Trt
Pbf
Tr t
tBu
Trt
tBu
tBu
tBu
Trt Pbf
Pbf
tBu
tBu
tBu
Trt
N S
O
O
NC
S COOEt
Trt
CICRGNGYCGSGSDGGVCPX3ILX1X2CRRDSDCPGABoc
Trt
Trt
Pbf
Trt
tBu
Trt
tBu
tBu
tBu
Trt Pbf
Pbf
tBu
tBu
tBu
TrtTrt
CICRGNGYCGSGSDGGVCPX3ILX1X2CRRDSDCPGABoc
Trt
Trt
Pbf
Trt
tBu
Trt
tBu
tBu
tBu
Trt Pbf
Pbf
tBu
tBu
tBu
TrtTrt
CICRGNGYCGSGSDGGVCPX3ILX1X2CRRDSDCPGAH
a
b
c
d
e
Hmb
Hmb
Hmb
te-MCoTI analogues  
Scheme 2 Synthetic route for SPPS synthesis of MCoTI cyclotide 
backbone thioester (te-MCoTI) analogues, starting from sulfamylbutyryl 
AM resin. MCoTI-I: X1 = Q, X2 = R, X3 = K; MCoTI-II: X1 = X2 = X3 = 
K; MCoTI-II analogues: X1 = X2 = K, X3 = R, Q, F, V, A or AKQ. 5 
Protecting groups: Boc: tert-butyoxycarbonyl; Trt: trityl; Fmoc: 
9-fluorenylmethoxycarbonyl; Pbf: 2,2,4,6,7-pentamethyl dihydrobenzo 
furan-5-sulfonyl; Hmb: hydroxy-4-methoxybenzyl (on backbone 
nitrogen). See Table 3 for overall yields of linear thioesters. Conditions: 
a) Fmoc-Ala-OH, DIPEA, PyBOP, -20 °C, 8 h; b) Fmoc/tBu SPPS; c) 10 
NMP, DIEPA, iodoacetonitrile (excess), 24 h, r.t.; d) sodium 
thiophenolate (cat.), ethyl 3-mercaptopropionate, DMF, 16 h, r.t.; e) TFA, 
H2O, EDT, TIPS (94:2.5:2.5:1). 
 In addition to the naturally-occurring MCoTI-I and MCoTI-
II cyclotides, a focussed series of MCoTI-II analogues bearing 15 
alternative residues in place of Lys10 was designed to enable 
a systematic investigation of the influence of this position on 
protease inhibition. Lys10 is recognised as the key 
determinant of binding to trypsin by analogy to well-
characterised homologous cystine-knot trypsin inhibitors such 20 
as EETI,29,43 and occupies the P1 position in the substrate 
binding site. Engineering changes at this residue would 
therefore be expected to alter inhibitory activity against 
trypsin, and potentially enable the development of inhibitors 
of alternative proteases whose activity depends on the 25 
presence of a residue other than Lys at P1, by analogy with 
previous work on peptide-based protease inhibitors.44-46 
Accordingly, open chain thioester MCoTI-II analogues (te-
MCoTI) bearing positively charged (Arg), hydrophobic (Val, 
Ala), aromatic (Phe) or amide (Gln) side chains were 30 
synthesised (Scheme 2b), along with one analogue with an 
expanded active loop (Ala-Lys-Gln) to investigate the 
versatility of the synthetic strategy with a longer backbone. 
 Backbone cyclisation of the linear thioesters via TZ-NCL 
was achieved under standard NCL conditions (100 mM 35 
ammonium carbonate buffer, pH 7.5), and in the presence of a 
reducing agent such as tricarboxyethyl phosphine (TCEP) the 
reduced cyclic backbone with six free cysteine thiols was 
isolated. Mild oxidative refolding by exposure to air in the 
presence of a suitable disulfide bond-exchange mediator 40 
(glutathione, reduced form) resulted in smooth conversion to a 
new product within minutes, as determined by reverse-phase 
HPLC (RP-HPLC). Analysis of this material by MALDI-TOF 
showed the formation of 3 disulfide bonds, and the native 
cyclotide fold of synthetic MCoTI-II was confirmed by NMR 45 
following the protocols of Craik et al.,23 and in inhibition 
studies (see below). Optimal results were obtained by 
combining cyclisation and refolding in a one-pot reaction, 
whereby the linear thioester is treated with glutathione in the 
same buffer, producing the target cyclotide in excellent 50 
overall yield (Scheme 3). The extended MCoTI-II variant 
MCoTI-II[AKQ] was formed in comparable yield and purity, 
suggesting that the MCoTI-II cyclotide fold tolerates the 
presence of additional residues in this loop. 
S COOEtCICRGNGYCGSGSDGGVCPX3ILX1X2CRRDSDCPGAH
SGSDGGVCPX3ILX1X2CRRDSDCPGACICRGNGYCG
SGSDGGVCPX3ILX1X2CRRDSDCPGACICRGNGYCG
aThia-zip NCL
Oxidative
refolding
te-MCoTI analogues
MCoTI analogues  55 
Scheme 3 One-pot TZ-NCL-refolding of linear precursor thioester (te-
MCoTI) analogues; X1, X2, X3: see Scheme 2. Solid bond: backbone 
cyclisation; dashed bonds: disulfide bridges. See Table 4 for isolated yield 
of target cyclotide after purification by RP-HPLC. Conditions: a) 
glutathione (1 mM, reduced form), aqueous ammonium carbonate (100 60 
mM, pH 7.4), r.t., 24 h. The intermediate head-to-tail cyclic peptide 
undergoes spontaneous refolding under these conditions to yield the target 
cyclotide in a one-pot reaction. 
Protease inhibition by engineered cyclotides 
With a variety of natural and engineered MCoTI cyclotides in 65 
hand, we next analysed their activity against a panel of 
proteases (Table 1). As previously determined for the natural 
products, synthetic MCoTI-I and MCoTI-II are extremely 
potent trypsin inhibitors, with Ki values in the low-pM 
range.29 MCoTI-II[R], which contains a conservative 70 
substitution that is tolerated in trypsin substrates, also 
maintains the potency of the parent natural product. These 
cyclotides also proved to be highly selective for trypsin: all 
other analogues tested had 103-4-fold lower activity in the 
assay, emphasising the importance of a positively-charged 75 
residue at P1. Activity was effectively switched to 
chymotrypsin when Lys10 was changed to match the preferred 
P1 residue (Phe), with only MCoTI-II[F] showing low-nM 
activity against this enzyme, although other uncharged 
residues (Q, V, A) were also tolerated to some degree. The 80 
MCoTI cyclotides appear to be selective inhibitors for trypsin 
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family proteases, exhibiting micromolar or higher Ki against 
the serine proteases thrombin and subtilisin. Remarkably 
however, MCoTI-II[Q] and MCoTI-II[AKQ] show significant 
activity against 3C protease from foot-and-mouth-disease 
virus (FMDV 3Cpro),47 a recently identified cysteine protease 5 
essential for replication in this virulent pathogen. Inhibition is 
specific to these cyclotides, which contain elements of the 
preferred P4-P1 residues (PAKQ) of FMDV 3Cpro,48 with other 
cyclotide analogues showing no detectible activity. 
Crystallography studies have shown that FMDV 3Cpro, like 10 
other picornaviral cysteine proteases, exhibits structural 
homology to mammalian serine proteases including a 
chymotrypsin-like fold, which may favour the inhibitory 
activity of MCoTI cyclotides against this target.47,48 MCoTI-
II[Q] and MCoTI-II[AKQ] represent the first known protein-15 
based inhibitors of this important viral protease. 
Table 1 Inhibition activity (Ki) of naturally-occurring and engineered 
MCoTI cyclotides against trypsin, chymotrypsin, thrombin and FMDV 
3C protease. Note that the units for activity against trypsin and 
chymotrypsin are pM and nM respectively, and are µM for all other 20 
enzymes. 
Cyclotide 
Lys10 = [X] 
Ki values 
Trypsin 
(pM) 
Chymo-
trypsin 
(nM) 
Thrombin 
(µM) 
Subtilisin 
(µM) 
FMDV 
3Cpro 
(µM) 
MCoTI-I 29 ± 2 >104 >100 >100 >100 
MCoTI-II 75 ± 5 >104 >100 >100 >100 
MCoTI-II[R] 85 ± 7 >104 >100 >100 >100 
MCoTI-II[Q] 5×106 2×103 >100 >100 41 ±25 
MCoTI-II[F] 0.4×106 9.8 ±0.7 >100 49 ±4 >100 
MCoTI-II[V] >109 >104 >100 >100 >100 
MCoTI-II[A] >109 >104 >100 >100 >100 
MCoTI-II [AKQ] >109 >104 >100 >100 56 ±35 
a Footnote text. 
 
Chemoenzymatic synthesis of engineered MCoTI cyclotides 
Having established the inhibition activity and selectivity 25 
profile of the MCoTI cyclotides, we next sought to design a 
simplified synthesis of the head-to-tail cyclic cystine-knot 
scaffold by utilising a biomimetic (chemoenzymatic) 
approach. It is known that related cyclic peptidic trypsin 
inhibitors such as BPTI49,50 and SFTI-I51 bind to the enzyme 30 
active site in an inter-convertible mixture of non-covalent 
enzyme-peptide complex and covalently-bound peptidyl-
enzyme, a non-productive analogue of the acyl-enzyme 
intermediate in proteolytic cleavage. Building on previous 
work that shows that proteases can be induced to synthesise a 35 
peptide bond by careful control of the reaction conditions,52-55 
we reasoned that a linear cyclotide backbone acid bearing the 
P1 residue at the C-terminus might be a viable substrate for 
protease-mediated ligation, thus enabling synthesis of the 
cyclic backbone without the need for a C-terminal thioester.  40 
 An initial proof-of-principle experiment was carried out to 
test whether this concept could be applied for total synthesis 
of the naturally-occurring MCoTI-II. The requisite Lys10 C-
terminal acid open-chain backbone (oc-MCoTI-II) was 
synthesised in excellent overall yield using Fmoc/tBu SPPS. 45 
As in our previous syntheses of MCoTI cyclotides, 
aspartimide formation at the DG motif was effectively 
suppressed by the introduction of Hmb protection at the 
glycine backbone nitrogen.42 oc-MCoTI-II was refolded to the 
cystine-knot peptide rf-MCoTI-II by exposure to our standard 50 
oxidative refolding conditions (Scheme 4), and no misfolded 
peptide was observed by HPLC. In initial attempts to achieve 
backbone ligation, mixtures of rf-MCoTI-II and trypsin (up to 
1:1 ratio) were combined in 100 mM phosphate buffer (pH 
7.4). In each case, some cyclisation to MCoTI-II was seen by 55 
MALDI and HPLC by comparison with authentic MCoTI-II 
prepared by one-pot TZ-NCL chemistry, but contamination 
with peptides resulting from protease auto-digestion precluded 
further analysis and purification. 
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Scheme 4 Chemoenzymatic synthesis of MCoTI-II and analogues from 
open-chain acids (oc-MCoTI, prepared by SPPS), via refolded cystine-
knot intermediates (rf-MCoTI). PSP: polymer supported serine protease 
(trypsin or chymotrypsin); X3 = K or F. Conditions: a) 0.1 M ammonium 
carbonate (pH 7.8)/acetonitrile 1:1, 1 mM glutathione (reduced form); b) 65 
PSP (1 equiv.), 100 mM sodium phosphate (pH 7.0); c) wash (H2O), then 
0.1% TFA(aq). 
 Trypsin immobilised on Sepharose beads (polymer-
supported trypsin, PST) is used widely for sequencing 
applications, since contamination through autocleavage is 70 
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greatly suppressed. We considered that PST might be 
employed as a polymer-supported ligase for clean MCoTI 
macrolactamisation. Furthermore, the newly formed cyclotide 
should remain tightly bound to the solid support, enabling 
facile in situ affinity purification.‡ In a typical binding 5 
procedure (Scheme 4) a two-fold excess of rf-MCoTI-II was 
incubated with sequencing grade PST suspended in phosphate 
buffer (100 mM, pH 7.4) at 37 °C for 15 min, after which the 
beads were washed several times with buffer. We 
hypothesised that increased protonation at the trypsin active 10 
site might result in release of the cyclotide from the putative 
cyclotide–enzyme complex in a non-denaturing and pH-
dependent manner, and thus allow the relatively costly PST to 
be recycled. Gratifyingly, upon treatment with 0.1% aqueous 
TFA (pH ~3) in deionised water MCoTI-II was released from 15 
PST in 92% yield, and in high purity (Figure 2). MCoTI-II 
synthesised by this chemoenzymatic method was identical in 
all respects to naturally occurring MCoTI-II.18,19,29,36 
Interestingly, concomitant release of a small amount (8%) of 
rf-MCoTI-II is observed, although it was absent from the 20 
flow-through from the wash steps. Incubating pure MCoTI-II 
with PST under the same conditions yielded an identical 
mixture, strongly suggesting that this ~10:1 ratio reflects the 
equilibrium mixture of MCoTI-II-trypsin complex to peptidyl-
enzyme intermediate, similar to that previously noted by Craik 25 
et al. in related studies on SFTI-I.51 It was found that by 
virtue of the non-denaturing elution conditions, PST could be 
reused in at least five cycles of protease-mediated ligation 
with no detectable loss of activity. In summary, PST-mediated 
ligation effectively combines macrolactamisation with on-30 
bead affinity purification; the cyclotide is bound as a 1:1 
trypsin–cyclotide complex, as evidenced by the ability of 
MCoTI-II to titrate the trypsin active site, necessitating a 
stoichiometric quantity of PST relative to rf-MCoTI-II. 
Remarkably, backbone refolding and PST-mediated 35 
ligation/affinity purification may even be combined in a single 
pot by simple incubation of crude oc-MCoTI-II with PST in 
buffer containing 1 mM glutathione to give MCoTI-II and 
~10% residual rf-MCoTI-II in very high purity upon elution 
with 0.1% TFA.  40 
 
5 7 9 11 13 15 17 Time (s) 
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Figure 2 HPLC traces showing conversion of open-chain acid to refolded 
backbone to target cyclotide. A: purified oc-MCoTI-II; B: purified rf-
MCoTI-II; C: product after elution of MCoTI-II from PST with 0.1% 
TFA(aq). Gradient: 0 to 85% MeCN in H2O (+ 0.1% TFA) over 40 45 
minutes. 
 This facile new route to MCoTI-II was explored in a series 
of experiments that show that PST possesses ligase specificity 
for positively charged (Arg/Lys) residues at P1 in the 
inhibitory loop. The open-chain forms of the naturally 50 
occurring cyclotide MCoTI-I (P1=Lys) and three MCoTI-II 
analogues in which P1 was changed to Arg, Gln or Phe (Table 
2) were synthesised by SPPS, and subjected to the refolding 
and PST-mediated ligation conditions described above. 
Folded macrocyclic MCoTI-I and MCoTI-II[R] were 55 
produced in high purity by comparison with authentic samples 
prepared by TZ-NCL, whilst MCoTI-II[Q] and MCoTI-II[F] 
appear to be cleaved at one or more positions on the 
backbone, with multiple peaks observed in the RP-HPLC 
trace. As for MCoTI-II, ligation reactions yielded MCoTI-I 60 
(93%) and MCoTI-II[R] (94%) together with refolded starting 
material in a 10:1 ratio. However, re-engineering the 
inhibitory loop to contain P1=Phe enables ligation by 
chymotrypsin. Thus oc-MCoTI-II[F] was refolded and 
incubated with commercially available sequencing-grade 65 
polymer-supported chymotrypsin (PSC) to yield MCoTI-II[F] 
analogue cyclotide (90%), with 10% residual rf-MCoTI-II[F]. 
Furthermore, the reaction is highly specific: rf-MCoTI-II[F] is 
the only MCoTI analogue susceptible to ligation with PSC; 
other cyclotides are either unreactive or partially digested 70 
under the same conditions. Qualitative selectivity in the ligase 
reaction is therefore directly related to potency of inhibition: 
only the most potent inhibitory cyclotides are susceptible to 
ligation with a given solid-supported protease. 
Table 2 Yield of cyclotides and intermediates synthesised by SPPS, 75 
refolding and protease-mediated backbone ligation. 
Cyclotide 
Lys10 = [X] 
Yield (%) 
SPPS 
oc-Cyclotide 
Refolding 
rf-Cyclotide  
PST 
Cyclotide 
PSC  
Cyclotide  
MCoTI-I 7 72 93a 0 
MCoTI-II 8 65 92 a 0 
MCoTI-II[R] 13 59 94 a 0 b 
MCoTI-II[F] 5 64 0b 90 a 
MCoTI-II[Q] 10 60 0b 0 
a In each case, residual rf-cyclotide was returned in 7-10% yield after in 
situ affinity purification. b Starting material partially digested. 
Conclusions 
In summary, we have achieved the total synthesis of MCoTI-I, 80 
MCoTI-II and MCoTI cyclotide analogues in a strategy that 
combines optimised SPPS of the peptide backbone bearing an 
N-terminal cysteine and C-terminal thioester, native chemical 
ligation/cyclisation via an efficient thia-zip reaction, and 
refolding under mild conditions to yield the native cystine-85 
knot topology. At up to 36 residues in size, these compounds 
are among the largest synthetic cyclotides reported to date, 
and their syntheses demonstrate the versatility and efficiency 
of this synthetic approach. Furthermore, we have developed a 
biomimetic strategy for the synthesis of MCoTI cyclotides 90 
bearing a Lys10 or Phe10 residue, utilising commercially 
available polymer-supported proteases that can act as a ligase 
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for the refolded cyclotide backbone. This chemoenzymatic 
approach displays even greater efficacy than the non-
enzymatic route described above, and provides for in situ 
affinity purification of the target cyclotides. The ease with 
which oc-MCoTI analogues fold and ligate in the presence of 5 
an appropriate protease raises the possibility that biosynthesis 
of MCoTI cyclotides might follow a protease/ligase pathway 
in vivo, in a similar manner to the structurally related Kalata 
cyclotide family.32 
 To realise the full potential of cyclotides as stable scaffolds 10 
for drugs and as tools for chemical genetics it is necessary to 
demonstrate that their structure may be re-engineered without 
loss of activity. We have reported here the first instance of 
redesigning the active loop of a cyclotide to redirect its 
specificity towards alternative targets whilst retaining 15 
moderate to high affinity. Proteases are of central importance 
as current and potential drug targets in a wide range of 
diseases. Foot-and-mouth disease, a disease of cloven-hoofed 
livestock, exacts a severe economic toll on affected 
communities.56 In the work presented here, the first cyclotide 20 
inhibitors of the foot-and-mouth viral 3C protease are 
reported,48,57 based on a re-engineered MCoTI-II cyclotide 
scaffold. Though the potency of these first generation 
inhibitors is moderate (low μM), it is notable that cyclotides 
based on a trypsin inhibitor scaffold exhibit activity against 25 
this cysteine protease. 
 We anticipate that the efficient chemical and 
chemoenzymatic routes presented here will be readily adapted 
to ligation, screening and in situ purification of cyclotide-
based libraries.2,26 In particular, polymer-supported proteases 30 
represent a potentially powerful platform for screening 
combinatorial libraries of precursor peptides for sequences 
that can adopt a native cyclotide fold, and for the 
identification of novel cyclotide-based protease inhibitors 
with inherent stability in vivo.17,58 35 
Experimental 
Materials and Methods 
All general laboratory chemicals obtained from chemical 
suppliers (Novabiochem UK or Sigma-Aldrich Chemical Co.) 
were used without further purification. Peptides were 40 
synthesised using an Advanced ChemTech Apex 396 multiple 
peptide synthesiser (Advanced Chemtech Europe, Cambridge, 
UK). Purification of crude peptides was performed on a 
Gilson semi-preparative RP-HPLC system (Anachem Ltd., 
Luton, UK) equipped with 306 pumps and a Gilson 155 45 
UV/Vis detector. Analytical RP-HPLC was performed on a 
Gilson analytical HPLC system (Anachem Ltd., Luton, UK) 
equipped with a Gilson 151 UV/Vis detector and Gilson 234 
auto injector, on a C-18 stationary phase. Peptide purification 
was achieved using preparative reverse-phase HPLC using a 50 
HICHROM C18 Column (250 × 21.2 mm). For both HPLC 
systems, the peptide bond absorption was detected at 223 nm. 
The following elution methods were used: Method A: 20 to 
50% MeCN in H2O over 40 min; Method B: 0 to 85% MeCN 
in H2O over 40 min. The mobile phases contained 0.1% 55 
HPLC-grade TFA as an ion pairing agent and were degassed 
with helium. All peptides and reaction mixtures were analysed 
using Method B unless otherwise specified. Solid phase 
resins, preloaded Wang resin and 4-sulfamylbutyryl AM resin, 
were purchased from Novabiochem UK. The resin loadings 60 
were as follows: Fmoc-Lys(Boc)-Wang : 0.69 mmol/g; Fmoc-
Phe-Wang : 0.74 mmol/g; Fmoc-Gln(Trt)-Wang : 0.62 
mmol/g; Fmoc-Arg(Pbf)-Wang : 0.51 mmol/g; 4-
sulfamylbutyryl AM resin : 1.1 mmol/g. Amino acids: N-α-9-
Fluorenylmethoxycarbonyl (N-α-Fmoc) protected amino acid 65 
were obtained from Novabiochem UK with the following 
side-chain protecting groups. Ala, Arg(Pbf), Asn(Trt), 
Asp(tBu), Cys(Trt), Gly, Ile, Leu, Lys(Boc), Pro, Ser(tBu), 
Tyr(tBu), Val and Fmoc-Asp(OtBu)-(Hmb)Gly-OH were 
purchased from Novabiochem UK. Reagents: Peptide 70 
synthesis grade dimethylformamide (DMF) from Rathburn 
Chemicals UK. Benzotriazole-1-yl-oxy-tris-pyrrolidino-
phosphonium hexafluorophosphate (PyBOP), N-
hydroxybenzotriazole (HOBt), diisopropylethylamine 
(DIPEA) and 2-(1H-benzotriazole-1-yl)-1,1,3,3-75 
tetramethylaminium hexafluorophosphate (HBTU) were 
purchased from Novabiochem UK and Sigma-Aldrich. Dry 
tetrahydrofuran (THF) and N,N-dimethylsulfoxide (DMF), 
chloroform, dimethylsulfoxide (DMSO), dichloromethane 
(DCM), N-methyl pyrrolidone (NMP), methanol, piperidine, 80 
thioanisole, t-butylmethylether (TBME), trifluoroacetic acid 
(TFA), ethanedithiol (EDT), iodoacetonitrile, 3-mercaptoethyl 
propionate, sodium thiophenolate, monobasic and dibasic 
sodium phosphate, and trimethylsilylisopropane (TIPS) were 
regent grade from Sigma-Aldrich. A ‘deprotection mixture’ of 85 
TFA:H2O:EDT:TIPS (94:2.5:2.5:1) was used for cleavage and 
deprotection reactions. 
General procedures 
Loading of sulfamylbutyryl AM resin with Fmoc-Ala-OH: 
Sulfamylbutyryl AM resin (250 mg, 0.172 mmol) was swollen 90 
in DMF (3 mL) for 1 hour at ambient temperature. To this 
solution were added Fmoc-Ala-OH (268 mg, 0.86 mmol) and 
DIPEA (264 µL, 1.6 mmol). The reaction mixture was left to 
stir for 15 minutes followed by cooling to -20 °C for 20 
minutes. Then PyBOP (447 mg, 0.86 mmol) was added and 95 
the reaction mixture stirred for 8 hours at -20 oC. The reaction 
mixture was left to warm to ambient temperature overnight. 
The resin was recovered by filtration and washed with DMF 
(3 × 2 mL). The coupling was repeated using the same 
procedure and washed with DMF (3 × 2 mL), DCM (3 × 100 
2 mL) and MeOH (3 × 2 mL), respectively. The loaded resin 
was dried in vacuo. The coupling efficiency was assessed as 
follows: typically 2 mg of thoroughly-dried resin (or peptidyl 
resin) was incubated with a solution of 1 mL 20% piperidine 
in DMF, and left for 1 hour. The solution was then filtered off 105 
and the filtrate measured for its absorbance at 290 nm or 
301 nm (ε290 nm = 5800 M-1 cm-1, ε301 nm = 7800 M-1 cm-1) 
against a blank of 20% piperidine in DMF. Loading efficiency 
was ~81%. 
Solid Phase Peptide Synthesis: Peptide synthesis was carried 110 
out in peptide synthesis grade DMF. Resin preloaded with 
appropriate amino acid (25 µmol per well) was swelled in 
DMF for 60 minutes before each coupling cycle, N-α-amino 
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Fmoc group was removed with 20% (v/v) piperidine in DMF 
for 15 minutes, with two further repetitions. A fivefold excess 
of amino acid over resin reactive groups (125 µmol, 250 µL of 
a 0.5 M solution) was used for each coupling. In situ 
activation and coupling was carried out for 45 min with a 5 
mixture of HBTU/HOBt (125 µmole, 250 µL of a 0.5 M 
solution) and DIPEA (125 µmole, 250 µL of 0.5 M solution). 
The peptide was washed with DMF (3 × 1 mL) between each 
deprotection and coupling step. A typical cycle consisted of 
deprotection, DMF wash, coupling and a further DMF wash. 10 
The N-α-Fmoc protection at the final residue was removed at 
the end of the synthesis under the usual conditions. After 
synthesis was complete, the fully protected resin-bound 
MCoTI was removed from the synthesiser, washed several 
times (3 × 2 mL DMF, 3 × 2 mL DCM, 3 × 2 mL MeOH) and 15 
dried in vacuo. Asp7Gly6 was introduced as a dipeptide 
(Fmoc-Asp(OtBu)-(Hmb)Gly-OH) and coupled for 2 hours. 
Cys34 was introduced as Boc-Cys(Trt)-OH for te-MCoTI 
syntheses. Residues were double-coupled where appropriate 
(see Table 3). 20 
Activation and displacement from sulfamyl resin: 
Activation: fully protected MCoTI bound to sulfamyl resin 
(25 µmol) was swelled in 1.5 mL of dry NMP for 1 hour. To 
this solution was added DIEPA (200 µL, 1.1 mmol) followed 
by excess iodoacetonitrile (180 µL filtered through basic 25 
alumina prior to use). The reaction flask was shielded from 
light and agitated for 24 hours at ambient temperature. The 
resin was washed with NMP (5 × 5 mL), DCM (5 × 5 mL), 
MeOH (5 × 5 mL) and dried in vacuo. Displacement: to the 
activated resin were added a small amount of sodium 30 
thiophenolate (1.6 mg), ethyl 3-mercaptopropionate (160 µL, 
1.25 mmol) and DMF (500 µL). The reaction mixture was 
agitated overnight at ambient temperature. The resin was 
filtered and the filtrate was evaporated to dryness in vacuo to 
yield fully protected MCoTI thioester which was subsequently 35 
treated with 2 mL of deprotection mixture over 3 hours to give 
the corresponding te-MCoTI. Precipitation and purification 
were conducted as described below.  
Deprotection and cleavage from Wang resin: Cleavage and 
deprotection of peptides was achieved by adding 1.5 mL of 40 
deprotection mixture to dry peptide bound resin (25 µmol). 
The mixture was agitated on an orbital shaker for up to 3 
hours and then filtered. The resin was washed twice with a 
small volume of TFA and the combined washings and filtrate 
were precipitated with 10 mL ice cold TBME. The mixture 45 
was centrifuged at 5000 rpm for 20 minutes at 0 °C, the 
supernatant discarded and the remaining peptide washed with 
a fresh aliquot of TBME. The process was repeated three 
times to ensure complete removal of all organic impurities. 
The crude peptide was dried in a desiccator over silica gel to 50 
yield an off-white solid.  
Peptide Purification: A small sample of crude peptide was 
analysed by analytical preparative RP-HPLC before purifying 
by preparative HPLC. Individual fractions from preparative 
reverse-phase HPLC were analysed using analytical reverse-55 
phase HPLC, and pure fractions combined and diluted to 
<10% MeCN with deionised water. The peptide was obtained 
as a white solid after lyophilisation on a Christ Alpha 2-4 
freeze dryer (Osterode am Harz Germany). Mass 
identification by Matrix-Assisted Laser Desorption/Ionisation 60 
Time of Flight Mass spectrometry (MALDI-TOF MS) was 
performed using α-Cyano-4-hydroxycinnamic acid as the 
matrix. 
Synthesis of cyclotides via thia-zip native chemical 
ligation: Glutathione (0.3 mg, 1 µmol) was dissolved in 1 mL 65 
of 0.1 M carbonate buffer. This solution was added to te-
MCoTI (0.28 µmol) which was dissolved in 1 mL of 
acetonitrile and the reaction mixture left for 24 hours at room 
temperature. The reaction mixture was then diluted 2-fold in 
water and purified by preparative RP-HPLC using Method A. 70 
Fractions were collected, analysed by analytical HPLC, pure 
fractions pooled and lyophilized to yield the product 
cyclotide. 
Synthesis of rf-MCoTI-I, II and analogues via oxidative 
refolding: oc-MCoTI acid (0.28 µmol) was dissolved in 1 mL 75 
of 0.1 M ammonium carbonate buffer. To this solution was 
added glutathione (0.3 mg, 1 µmol), which was dissolved in 
acetonitrile (1 mL). The reaction mixture was allowed to stand 
for 48 hours at room temperature, diluted two-fold with water 
and purified by RP-HPLC using Method A. Fractions were 80 
collected, analysed using Method B, pooled and lyophilised.  
Synthesis of cyclotides via ligation by immobilised 
protease: Cyclisation using immobilised trypsin: Immobilised 
trypsin (500 µL of re-suspended beads) was washed with 0.1 
M phosphate buffer (5 × 1 mL, pH 7.4) before use. rf-MCoTI 85 
peptide (0.03 µmol) was dissolved in 500 µL 0.1 M phosphate 
buffer pH 7.4 and added to immobilised trypsin. The reaction 
mixture was incubated at 37 °C for 15 minutes, mixed on a 
vortex mixer for 10 s and centrifuged at 14000 rpm for 5 
minutes. The supernatant was removed from immobilised 90 
trypsin which was subsequently washed with water (5 × 
1 mL); the reaction mixture was mixed and centrifuged as 
above at each washing. 0.1% TFA in water was added and the 
mixture mixed and left to stand for 5 minutes, the supernatant 
was recovered, and this procedure was repeated. The 95 
combined TFA washings were analysed by analytical HPLC 
and MALDI-MS. Cyclisation using immobilised 
chymotrypsin: The reaction was performed exactly as for 
immobilised trypsin, except that 25 mg immobilised 
chymotrypsin was weighed out and washed as above. 100 
Peptide concentration determination for MCoTI-I, II and 
MCoTI-II[R]: The concentration of active MCoTI cyclotide 
was determined by titration with trypsin (adapted from Ref. 
12). Microprotein at a range of concentrations (1 µM to 
0.1 nM, 50 µL) in TBS pH 7.6 (Tris buffered saline: 50 mM 105 
Tris.HCl, 150 mM NaCl, 0.01% Tritron® X-100, 0.02% 
sodium azide) was incubated with trypsin (25 nM, 50 µL) for 
30 minutes at 37 °C in a 96-well plate (Falcon MicrotestTM 
96). Carbobenzoxy-L-arginine-7-amino-4-methyl coumarin 
(75 µM, 100 µL) was added to the solution and the 110 
absorbance measured at room temperature with excitation and 
emission wavelengths at 360 and 465 nm respectively. The 
concentration of active cyclotide was determined from 
inhibition curves obtained in two separate experiments 
assuming a 1:1 interaction between inhibitor and trypsin. 115 
Peptide concentration determination for MCoTI-II[F] and 
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MCoTI-II[Q]: These MCoTI-II analogues have relatively low 
inhibition activity against trypsin, and so a standard addition 
method was used to determine peptide concentration using 
analytical HPLC. A standard addition graph from MCoTI-I, II 
and MCoTI-II[R] was plotted by varying the active peptide 5 
concentration (200 µM to 10 µM) versus peak area measured 
at 223 nm and, by comparison of peak areas, used to 
determine the concentration of microproteins MCoTI-II[F] 
and MCoTI-II[Q]. 
Inhibition Kinetics: All inhibition kinetics were determined 10 
by competitive binding assays at 37 °C on a Cytofluor series 
400 microplate reader (Perseptive Biosystem, Warrington, 
UK), using Falcon MicrotestTM 96-well plates. TBS pH 7.6 
was prepared for trypsin and chymotrypsin assays. The 
equilibrium dissociation constant (Ki) for the complex 15 
between trypsin or chymotrypsin and the cyclotide was 
determined by using enzyme concentrations lower than the Ki. 
Thus, proteases (0.005 nM, 50 µL trypsin or 0.5 nM, 50 µL 
chymotrypsin, 12.5 µM, 50 µL subtilisin and 1 nM, 50 µL 
thrombin) were incubated at a suitable range of concentrations 20 
of inhibitor in TBS for 1 hour. The measurement was started 
by the addition of substrate: (5 µM, 100 µL N-p-tosyl-Gly-
Pro-Arg-AMC (AMC: 7-amido-4-methyl coumarin) for 
trypsin and thrombin assays, or succinimidyl-Ala-Ala-Pro-
Phe-AMC (10 µM, 100 µL for chymotrypsin or 19 µM, 25 
100 µL for subtilisin assays). The initial rate of substrate 
hydrolysis was monitored by the cleavage of AMC from 
substrate at an excitation of 360 nm and emission of 460 nm. 
Cyclotide activity against FMDV 3Cpro was determined as 
described previously, using 617 nM, 50 µL FMDV 3Cpro, 50 30 
µM, 100 µL FRET substrate.59 Initial rate data were then 
fitted to determine Ki using the GraFit Software package 
(http://www.erithacus.com/grafit). All assays were reproduced 
3 times with fresh solutions of all reagents, and the standard 
deviation is given where appropriate. 35 
Additional Characterisation Data 
Table 3 Open-chain acids (oc-) and thioesters (te-) synthesised by SPPS.  
Cyclotide 
Lys10 = [X] 
Data 
Residues 
double-
coupled  
Yield MALDI-MS 
Retention 
time (min) 
(Method B) 
oc-MCoTI-I Ala21 Gly22 7% 
3507[M+H]+ 
1754[M+2H]2+ 12.4 
oc-MCoTI-II 
Ala21 
Gly22 
Ile34 
8% 3478[M+H]+ 12.3 
oc-MCoTI-II[R] 
Ala21 
Gly22 
Ile34 
13% 3505[M+H]
+ 
1753[M+2H]2+ 12.0 
oc-MCoTI-II[F] 
Ala21 
Gly22 
Ile34 
10% 3497[M+H]+ 14.4 
oc-MCoTI-II[Q] 
Ala21 
Gly22 
Ile34 
5% 3478[M+H]
+ 
1739[M+2H]2+ 12.3 
oc-MCoTI-II[AKQ] 
Ala21 
Gly22 
Ile34 
5% 
 
3676[M+H]+ 
 
10.2 
te-MCoTI-I  Val18 6% 3622[M+H]+ 14.8 
te-MCoTI-II  Ile14 Lys15 5% 
3594[M+H]+ 
1798[M+2H]2+ 14.4 
Val18 
te-MCoTI-II[R]  Ile14 Arg15 7% 3622[M+H]
+ 14.1 
te-MCoTI-II[F]  Ile14 Phe15 4% 
3613[M+H]+ 
1807[M+2H]2+ 15.4 
te-MCoTI-II[Q]  Ile14 Gln15 4% 
3593[M+H]+ 
1797[M+2H]2+ 14.6 
te-MCoTI-II[V] Ile14 Val15 4% 
3566[M+H]+ 
1783[M+2H]2+ 14.6 
te-MCoTI-II[A] Ile14 Ala15 4% 
3537[M+H]+ 
1769[M+2H]2+ 14.7 
te-MCoTI-II[AKQ] 
Ile14 
Gln15 
Lys16 
Ala17 
5% 3793[M+H]
+ 
1897[M+2H]2+ 14.5 
Table 4 Open-chain refolded (rf-) cyclotides synthesised by oxidative 
refolding and cyclotides synthesised by TZ-NCL and/or immobilised 
protease-mediated ligation.  40 
Cyclotide 
Lys10 = [X] 
Data 
Yield MALDI-MS 
Retention time 
(min) 
(Method B) 
rf-MCoTI-I 72% 3501[M+H]+ 10.5 
rf-MCoTI-II 65% 3472[M+H]
+ 
1737[M+2H]2+ 10.4 
rf-MCoTI-II[R] 59% 3500[M+H]
+ 
1751[M+2H]2+ 10.5 
rf-MCoTI-II[F] 60% 3491[M+H]
+ 
1746[M+2H]2+ 12.2 
rf-MCoTI-II [Q] 64% 3473[M+H]
+ 
1736[M+2H]2+ 10.6 
rf-MCoTI-II[AKQ] 36% 
 
3672[M+H]+ 
 
12.0 
MCoTI-I 68% a 3482[M+H]
+ 
1741[M+2H]2+ 12.3 
MCoTI-II 72% a 3454[M+H]
+ 
1727[M+2H]2+ 11.5 
MCoTI-II[R] 72% a 3483[M+H]
+ 
1742[M+2H]2+ 11.8 
MCoTI-II[F] 64% a 3474[M+H]
+ 
1737[M+2H]2+ 15.2 
MCoTI-II[V] 64% a 3427[M+H]
+ 
1713[M+2H]2+ 10.2 
MCoTI-II[A] 63% a 3399[M+H]
+ 
1699[M+2H]2+ 10.1 
MCoTI-II[AKQ] 71% a 3653[M+H]
+ 
1827[M+2H]2+ 11.7 
MCoTI-I 93% b 3482[M+H]
+ 
1742[M+2H]2+ 12.4 
MCoTI-II 92% b 3454[M+H]
+ 
1728[M+2H]2+ 11.4 
MCoTI-II[R] 94% b 3481[M]
+ 
1741[M+2H]2+ 11.8 
MCoTI-II[F] 
 90%
 b 3474[M+H]+ 15.4 
a Synthesised by TZ-NCL; b synthesised by immobilised protease-
mediated ligation. 
 
Notes and references 
a Department of Chemistry, Imperial College London, Exhibition Rd., 45 
London SW7 2AZ. Fax: (+44) (0)2075941139. E-mail: 
e.tate@imperial.ac.uk; r.leatherbarrow@imperial.ac.uk.  
We are grateful to the the BBSRC for a David Phillips Research 
Fellowship (to EWT), the Royal Thai Government for a research 
 This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  9 
studentship (to PT), and the European Union for Marie Curie Host 
Fellowships for Early Stage Research Training (to NR and PT). 
† Note that the term cysteine-knot is also used to describe this structural 
motif. 
‡ Subsequent to our first communication of the work presented here, PST 5 
was also described as a reagent for affinity purification of MCoTI-II 
expressed in E. coli.25 
1. D. J. Craik, M. Cemazar and N. L. Daly, Curr. Opin. Drug Discov. 
Devel., 2007, 10, 176-184. 
2. D. J. Craik, M. Cemazar, C. K. Wang and N. L. Daly, Biopolymers, 10 
2006, 84, 250-266. 
3. D. C. Ireland, C. K. Wang, J. A. Wilson, K. R. Gustafson and D. J. 
Craik, Biopolymers, 2007. 
4. K. R. Gustafson, T. C. McKee and H. R. Bokesch, Curr. Protein 
Pept. Sci., 2004, 5, 331-340. 15 
5. N. L. Daly, K. R. Gustafson and D. J. Craik, FEBS Lett., 2004, 574, 
69-72. 
6. C. V. Jennings, K. J. Rosengren, N. L. Daly, M. Plan, J. Stevens, M. 
J. Scanlon, C. Waine, D. G. Norman, M. A. Anderson and D. J. 
Craik, Biochemistry, 2005, 44, 851-860. 20 
7. C. Jennings, J. West, C. Waine, D. Craik and M. Anderson, Proc. 
Natl. Acad. Sci. USA, 2001, 98, 10614-10619. 
8. D. J. Craik and N. L. Daly, Protein Pept. Lett., 2005, 12, 147-152. 
9. M. Cemazar, N. L. Daly, S. Haggblad, K. P. Lo, E. Yulyaningsih and 
D. J. Craik, J. Biol. Chem., 2006, 281, 8224-8232. 25 
10. K. J. Rosengren, N. L. Daly, M. R. Plan, C. Waine and D. J. Craik, J. 
Biol. Chem., 2003, 278, 8606-8616. 
11. P. Seydel, C. W. Gruber, D. J. Craik and H. Dornenburg, Appl. 
Microbiol. Biotechnol., 2007, 77, 275-284. 
12. A. D. Gillon, I. Saska, C. V. Jennings, R. F. Guarino, D. J. Craik and 30 
M. A. Anderson, Plant J., 2007. 
13. D. J. Craik, D. G. Barry, R. J. Clark, N. L. Daly and L. Sando, J. 
Toxicol., Toxin Rev., 2003, 22, 555-576. 
14. T. Leta Aboye, R. J. Clark, D. J. Craik and U. Goransson, 
ChemBioChem, 2007. 35 
15. D. J. Craik, M. Cemazar and N. L. Daly, Curr. Opin. Drug Discov. 
Devel., 2006, 9, 251-260. 
16. D. J. Craik, S. Simonsen and N. L. Daly, Curr. Opin. Drug Discov. 
Devel., 2002, 5, 251-260. 
17. M. Werle, K. Kafedjiiski, H. Kolmar and A. Bernkop-Schnurch, Int J 40 
Pharm, 2007, 332, 72-79. 
18. M. E. Felizmenio-Quimio, N. L. Daly and D. J. Craik, J. Biol. Chem., 
2001, 276, 22875-22882. 
19. J. F. Hernandez, J. Gagnon, L. Chiche, T. M. Nguyen, J. P. Andrieu, 
A. Heitz, T. Trinh Hong, T. T. Pham and D. Le Nguyen, 45 
Biochemistry, 2000, 39, 5722-5730. 
20. D. J. Craik, N. L. Daly, T. Bond and C. Waine, J. Mol. Biol., 1999, 
294, 1327-1336. 
21. S. M. Simonsen, L. Sando, D. C. Ireland, M. L. Colgrave, R. 
Bharathi, U. Goransson and D. J. Craik, Plant cell, 2005, 17, 3176-50 
3189. 
22. M. Trabi and D. J. Craik, Plant cell, 2004, 16, 2204-2216. 
23. D. J. Craik and N. L. Daly, Mol. Biosyst., 2007, 3, 257-265. 
24. M. Cemazar and D. Craik, in J. Pept. Sci., 2008. 
25. J. A. Camarero, R. H. Kimura, Y. H. Woo, A. Shekhtman and J. 55 
Cantor, ChemBioChem, 2007, 8, 1363-1366. 
26. J. A. Camarero, R. H. Kimura, Y. H. Woo, J. Cantor and E. 
Steenblock, Chim. Oggi, 2007, 25, 20-23. 
27. S. Gunasekera, N. L. Daly, M. A. Anderson and D. J. Craik, IUBMB 
life, 2006, 58, 515-524. 60 
28. R. H. Kimura, A. T. Tran and J. A. Camarero, Angew. Chem. Int. Ed. 
Engl., 2006, 45, 973-976. 
29. O. Avrutina, H. U. Schmoldt, D. Gabrijelcic-Geiger, D. Le Nguyen, 
C. P. Sommerhoff, U. Diederichsen and H. Kolmar, Biol. Chem., 
2005, 386, 1301-1306. 65 
30. O. Avrutina, H. U. Schmoldt, H. Kolmar and U. Diederichsen, Eur. J. 
Org. Chem., 2004, 4931-4935. 
31. E. W. Tate, Signal Transduction, 2006, 6, 144-159. 
32. I. Saska, A. D. Gillon, N. Hatsugai, R. G. Dietzgen, I. Hara-
Nishimura, M. A. Anderson and D. J. Craik, J. Biol. Chem., 2007, 70 
282, 29721-29728. 
33. C. W. Gruber, M. Cemazar, R. J. Clark, T. Horibe, R. F. Renda, M. 
A. Anderson and D. J. Craik, J. Biol. Chem., 2007. 
34. P. Thongyoo, E. W. Tate and R. J. Leatherbarrow, Chem. Commun., 
2006, 2848-2850. 75 
35. P. Thongyoo, A. M. Jaulent, E. W. Tate and R. J. Leatherbarrow, 
ChemBioChem, 2007, 8, 1107-1109. 
36. A. Heitz, J. F. Hernandez, J. Gagnon, T. T. Hong, T. T. Pham, T. M. 
Nguyen, D. Le-Nguyen and L. Chiche, Biochemistry, 2001, 40, 7973-
7983. 80 
37. W. L. DeLano, The PyMOL molecular graphics system, 
http://www.pymol.org. 
38. J. P. Tam, Y. A. Lu, J. L. Yang and K. W. Chiu, Proc. Natl. Acad. 
Sci. USA, 1999, 96, 8913-8918. 
39. J. P. Tam and Y. A. Lu, Protein Sci., 1998, 7, 1583-1592. 85 
40. J. P. Tam and Y. A. Lu, Tetrahedron Lett., 1997, 38, 5599-5602. 
41. P. Heidler and A. Link, Bioorg. Med. Chem., 2005, 13, 585-599. 
42. R. G. Simmonds, Int. J. Pept. Protein Res., 1996, 47, 36-41. 
43. H. H. Niemann, H. U. Schmoldt, A. Wentzel, H. Kolmar and D. W. 
Heinz, J. Mol. Biol., 2006, 356, 1-8. 90 
44. J. D. McBride and R. J. Leatherbarrow, Curr. Med. Chem., 2001, 8, 
909-917. 
45. J. D. McBride, E. M. Watson, A. B. Brauer, A. M. Jaulent and R. J. 
Leatherbarrow, Biopolymers, 2002, 66, 79-92. 
46. D. Scarpi, J. D. McBride and R. J. Leatherbarrow, J. Pept. Res., 95 
2002, 59, 90-93. 
47. T. R. Sweeney, N. Roque-Rosell, J. R. Birtley, R. J. Leatherbarrow 
and S. Curry, J. Virol., 2007, 81, 115-124. 
48. S. Curry, N. Roque-Rosell, P. A. Zunszain and R. J. Leatherbarrow, 
Int. J. Biochem. Cell Biol., 2007, 39, 1-6. 100 
49. C. Groeger, H. R. Wenzel and H. Tschesche, Angew. Chem. Int. Ed. 
Engl., 1993, 32, 898-900. 
50. C. Groeger, H. R. Wenzel and H. Tschesche, Int. J. Pept. Protein 
Res., 1994, 44, 166-172. 
51. U. C. Marx, M. L. Korsinczky, H. J. Schirra, A. Jones, B. Condie, L. 105 
Otvos, Jr. and D. J. Craik, J. Biol. Chem., 2003, 278, 21782-21789. 
52. R. V. Ulijn, B. Baragana, P. J. Halling and S. L. Flitsch, J. Am. 
Chem. Soc., 2002, 124, 10988-10989. 
53. R. V. Ulijn, N. Bisek, P. J. Halling and S. L. Flitsch, Org. Biomol. 
Chem., 2003, 1, 1277-1281. 110 
54. D. Y. Jackson, J. Burnier, C. Quan, M. Stanley, J. Tom and J. A. 
Wells, Science, 1994, 266, 243-247. 
 10  |  Journal Name, [year], [vol], 00–00 This journal is © The Royal Society of Chemistry [year] 
55. D. Y. Jackson, J. P. Burnier and J. A. Wells, J. Am. Chem. Soc., 
1995, 117, 819-820. 
56. P. Kitching, J. Hammond, M. Jeggo, B. Charleston, D. Paton, L. 
Rodriguez and R. Heckert, Vaccine, 2007, 25, 5660-5664. 
57. S. Curry, N. Roque-Rosell, T. R. Sweeney, P. A. Zunszain and R. J. 5 
Leatherbarrow, Biochem Soc. Trans., 2007, 35, 594-598. 
58. K. P. Greenwood, N. L. Daly, D. L. Brown, J. L. Stow and D. J. 
Craik, Int. J. Biochem. Cell Biol., 2007, 39, 2252-2264. 
59. A. M. Jaulent, A. S. Fahy, S. R. Knox, J. R. Birtley, N. Roque-Rosell, 
S. Curry and R. J. Leatherbarrow, Anal. Biochem., 2007, 368, 130-10 
137. 
 
 
